H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on NRX Pharmaceuticals (NRXP – Research Report) today and set a price target of $2.00. The company’s shares opened today at $1.17.
According to TipRanks, Bernardino is a 5-star analyst with an average return of 19.8% and a 34.63% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Phio Pharmaceuticals, Edesa Biotech, and NRX Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NRX Pharmaceuticals with a $3.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.54 and a one-year low of $0.49. Currently, NRX Pharmaceuticals has an average volume of 380.4K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NRXP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Big Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm’s care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
Read More on NRXP:
